CNS metastases — ICI doublet retains intracranial activity; cabozantinib + nivolumab also...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | RF-RCC-TRANSFORMATION-PROGRESSION |
|---|---|
| Type | Red flag |
| Status | pending_clinical_signoff |
| Diseases | DIS-RCC |
| Sources | SRC-ESMO-RCC-2024 SRC-NCCN-KIDNEY-2025 |
Red Flag Origin
| Definition | CNS metastases — ICI doublet retains intracranial activity; cabozantinib + nivolumab also CNS-active. |
|---|---|
| Clinical direction | investigate |
| Category | transformation-progression |
Trigger Logic
{
"any_of": [
{
"finding": "cns_metastases_rcc",
"value": true
}
],
"type": "composite_clinical"
}
Notes
RCC brain-met rate ~10%.
Used By
Indications
IND-RCC-ADJUVANT-PEMBRO- IND-RCC-ADJUVANT-PEMBROIND-RCC-METASTATIC-1L-LENV-PEMBRO- IND-RCC-METASTATIC-1L-LENV-PEMBROIND-RCC-METASTATIC-1L-NIVO-CABO- IND-RCC-METASTATIC-1L-NIVO-CABOIND-RCC-METASTATIC-1L-NIVO-IPI- IND-RCC-METASTATIC-1L-NIVO-IPIIND-RCC-METASTATIC-1L-PEMBRO-AXI- IND-RCC-METASTATIC-1L-PEMBRO-AXIIND-RCC-METASTATIC-2L-BELZUTIFAN- IND-RCC-METASTATIC-2L-BELZUTIFANIND-RCC-METASTATIC-2L-CABOZANTINIB- IND-RCC-METASTATIC-2L-CABOZANTINIBIND-RCC-NON-CLEAR-CELL-1L-CABOZANTINIB- IND-RCC-NON-CLEAR-CELL-1L-CABOZANTINIBIND-RCC-VHL-DISEASE-BELZUTIFAN- IND-RCC-VHL-DISEASE-BELZUTIFAN